SCOPUS 정보 검색 플랫폼

Volumn 17, Issue 6, 2002, Pages 1057-1064

Daily oral pamidronate in women and men with osteoporosis: A 3-year randomized placebo-controlled clinical trial with a 2-year open extension

(12) Brumsen, Caroline a Papapoulos, Socrates E a Lips, Paul b Geelhoed Duijvestijn, Petronella H L M c Hamdy, Neveen A T a Landman, Jan Otto a McCloskey, Eugene V d Netelenbos, J Coen b Pauwels, Ernest K J a Roos, Jan C b Valentijn, Rob M e Zwinderman, Aeilko H a

a LEIDEN UNIVERSITY MEDICAL CENTER (Netherlands)

b VU UNIVERSITY MEDICAL CENTER (Netherlands)

c MEDICAL CENTER HAAGLANDEN (Netherlands)

d UNIVERSITY OF SHEFFIELD (United Kingdom)

e Red Cross Hospital Den Haag (Netherlands)

Author keywords

Bisphosphonate; Bone mineral density; Male osteoporosis; Pamidronate; Postmenopausal osteoporosis; Vertebral fractures

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; PLACEBO; ALENDRONIC ACID;

AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HIP; HUMAN; LUMBAR VERTEBRA; MALE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; ACUTE PHASE RESPONSE; ADULT; BONE MINERAL; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; ESOPHAGITIS; FEMUR NECK; GASTROINTESTINAL TOXICITY; MAJOR CLINICAL STUDY; POSTMENOPAUSE;

ADMINISTRATION, ORAL; AGED; BONE DENSITY; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HIP; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOPOROSIS; PLACEBOS; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0035999440 PISSN: 08840431 EISSN: None Source Type: Journal
DOI: 10.1359/jbmr.2002.17.6.1057 Document Type: Article

Times cited : (64)

References (43)

1
- 0004851872
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
- Fracture Intervention Trial Research Group
- (1996) Lancet , vol.348 , pp. 1535-1541
- Black, D.M.¹ Cummings, S.R.² Karpf, D.B.³ Cauley, J.A.⁴ Thompson, D.E.⁵ Nevitt, M.C.⁶ Bauer, D.C.⁷ Genant, H.K.⁸ Haskell, W.L.⁹ Marcus, R.¹⁰ Ott, S.M.¹¹ Tomer, J.C.¹² Quandt, S.A.¹³ Reiss, T.F.¹⁴ Ensrud, K.E.¹⁵

2
- 0032583492
- Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
- (1998) JAMA , vol.280 , pp. 2077-2082
- Cummings, S.R.¹ Black, D.M.² Thompson, D.E.³ Applegate, W.B.⁴ Barrett-Connor, E.⁵ Musliner, T.A.⁶ Palermo, L.⁷ Prineas, R.⁸ Rubin, S.M.⁹ Scott, J.C.¹⁰ Vogt, T.¹¹ Wallace, R.¹² Yates, A.J.¹³ LaCroix, A.Z.¹⁴

3
- 0034530951
- Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
- (2000) J Clin Endocrinol Metab , vol.85 , pp. 4118-4124
- Black, D.M.¹ Thompson, D.E.² Bauer, D.C.³ Ensrud, K.⁴ Musliner, T.⁵ Hochberg, M.C.⁶ Nevitt, M.C.⁷ Suryawanshi, S.⁸ Cummings, S.R.⁹

4
- 0032896590
- Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
- Fosamax International Trial Study Group
- (1999) Osteoporos Int , vol.9 , pp. 461-468
- Pols, H.A.¹ Felsenberg, D.² Hanley, D.A.³ Stepan, J.⁴ Munoz-Torres, M.⁵ Wilkin, T.J.⁶ Qin-Sheng, G.⁷ Galich, A.M.⁸ Vandormael, K.⁹ Yates, A.J.¹⁰ Stych, B.¹¹

5
- 0031006598
- Prevention of nonvertebral fractures by alendronate. A meta-analysis
- Alendronate Osteoporosis Treatment Study Groups
- (1997) JAMA , vol.277 , pp. 1159-1164
- Karpf, D.B.¹ Shapiro, D.R.² Seeman, E.³ Ensrud, K.E.⁴ Johnston, C.C.⁵ Adami, S.⁶ Harris, S.T.⁷ Santora, A.C.⁸ Hirsch, L.J.⁹ Oppenheimer, L.¹⁰ Thompson, D.¹¹

6
- 0033552255
- Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
- Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
- (1999) JAMA , vol.282 , pp. 1344-1352
- Harris, S.T.¹ Watts, N.B.² Genant, H.K.³ McKeever, C.D.⁴ Hangartner, T.⁵ Keller, M.⁶ Chesnut, C.H.⁷ Brown, J.⁸ Eriksen, E.F.⁹ Hoseyni, M.S.¹⁰ Axelrod, D.W.¹¹ Miller, P.D.¹²

7
- 12944291524
- Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
- (2000) Osteoporos Int , vol.11 , pp. 83-91
- Reginster, J.Y.¹ Minne, H.W.² Sorensen, O.H.³ Hooper, M.⁴ Roux, C.⁵ Brandi, M.L.⁶ Lund, B.⁷ Ethgen, D.⁸ Pack, S.⁹ Roumagnac, I.¹⁰ Eastell, R.¹¹

8
- 0035253489
- Effect of risedronate on the risk of hip fracture in elderly women
- (2001) N Engl J Med , vol.344 , pp. 333-340
- McClung, M.R.¹ Geusens, P.² Miller, P.D.³ Zippel, H.⁴ Bensen, W.G.⁵ Roux, C.⁶ Adam, S.⁷ Fogelman, I.⁸ Diamond, T.⁹ Eastell, R.¹⁰ Meunier, P.J.¹¹ Reginster, J.-Y.¹²

9
- 0018757367
- Treatment of Paget's disease of bone with 3-amino-l-hydroxypropylidene-1, 1-bisphosphonate (APD)
- (1979) Lancet , vol.1 , pp. 799-803
- Frijlink, W.B.¹ Te Velde, J.² Bijvoet, O.L.M.³ Heynen, G.⁴

10
- 0018741195
- Inhibition of osteolytic bone lesions by 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD)
- (1979) Lancet , vol.1 , pp. 803-805
- Van Breukelen, F.J.M.¹ Bijvoet, O.L.M.² Van Oosterom, A.T.³

11
- 0019309086
- APD in Paget's disease of bone, role of the mononuclear phagocyte system?
- (1980) Arthritis Rheum , vol.23 , pp. 1193-1204
- Bijvoet, O.L.M.¹ Frijlink, W.B.² Jie, K.³ Van de Linden, H.⁴ Meijer, C.J.L.M.⁵ Mulder, H.⁶ Van Paassen, H.C.⁷ Reitsma, P.H.⁸ Te Velde, J.⁹ De Vries, E.¹⁰ Wey, J.P.V.D.¹¹

12
- 0022358463
- Characteristics of bisphosphonate treatment of a patient with juvenile osteoporosis
- (1985) J Clin Endocrinol Metab , vol.61 , pp. 952-956
- Hoekman, K.¹ Papapoulos, S.E.² Peters, A.C.B.³ Bijvoet, O.L.M.⁴

13
- 0023839421
- Prevention of steroid-induced osteoporosis with (3-amino-I-hydroxypropylidene)-1, 1-bisphosphonate (APD)
- (1988) Lancet , vol.1 , pp. 143-146
- Reid, I.R.¹ King, A.R.² Alexander, C.J.³ Ibbertson, H.K.⁴

14
- 0024548317
- Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD
- (1989) Bone Miner , vol.5 , pp. 183-192
- Valkema, R.¹ Vismans, F.-J.F.E.² Papapoulos, S.E.³ Pauwels, E.K.J.⁴ Bijvoet, O.L.M.⁵

15
- 0026167084
- Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis
- (1991) Osteoporos Int , vol.1 , pp. 129-133
- Fromm, G.A.¹ Vega, E.² Plantalech, L.³ Galich, A.M.⁴ Mautalen, C.A.⁵

16
- 0028219647
- Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause
- (1994) Osteoporos Int , vol.4 , pp. 76-83
- Thiebaud, D.¹ Burckhardt, P.² Melchior, J.³ Eckert, P.⁴ Jacquet, A.F.⁵ Schnyder, P.⁶ Goebelt, C.⁷

17
- 0028598562
- Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis
- (1994) J Clin Endocrinol Metab , vol.79 , pp. 1595-1599
- Reid, I.R.¹ Wattie, D.J.² Evans, M.C.³ Gamble, G.D.⁴ Stapleton, J.P.⁵ Cornish, J.⁶

18
- 0030457760
- Role of oral pamidronate in preventing bone loss in postmenopausal women
- (1996) Osteoporos Int , vol.6 , pp. 480-485
- Lees, B.¹ Garland, S.W.² Walton, C.³ Ross, D.⁴ Whitehead, M.I.⁵ Stevenson, J.C.⁶

19
- 0034111392
- Intermittent oral disodium pamidronate in established osteoporosis: A 2-year double-masked placebo-controlled study of efficacy and safety
- (2000) Osteoporos Int , vol.11 , pp. 171-176
- Ryan, P.J.¹ Blake, G.M.² Davie, M.³ Haddaway, M.⁴ Gibson, T.⁵ Fogelman, I.⁶

20
- 0035172730
- Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone
- (2001) J Bone Miner Res , vol.16 , pp. 104-112
- Boutsen, Y.¹ Jamart, J.² Esselinckx, W.³ Devogelaer, J.P.⁴

21
- 0026553475
- The use of bisphosphonates in the treatment of osteoporosis
- (1992) Bone , vol.13 , pp. S41-S49
- Papapoulos, S.E.¹ Landman, J.O.² Bijvoet, O.L.M.³ Löwik, C.W.G.M.⁴ Valkema, R.⁵ Pauwels, E.K.J.⁶ Vermeij, P.⁷

22
- 0033678399
- Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women
- (2000) J Clin Endocrinol Metab , vol.85 , pp. 3109-3115
- Tonino, R.P.¹ Meunier, P.J.² Emkey, R.³ Rodriguez-Portales, J.A.⁴ Menkes, C.J.⁵ Wasnich, R.D.⁶ Bone, H.G.⁷ Santora, A.C.⁸ Wu, M.⁹ Desai, R.¹⁰ Ross, P.D.¹¹

23
- 0027252910
- The assessment of vertebral deformity: A method for use in population studies and clinical trials
- (1993) Osteoporos Int , vol.3 , pp. 138-147
- McCloskey, E.V.¹ Spector, T.D.² Eyres, K.S.³ Fern, E.D.⁴ O'Rourke, N.⁵ Vasikaran, S.⁶ Kanis, J.A.⁷

24
- 0032766023
- Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis
- (1999) Osteoporos Int , vol.9 , pp. 489-493
- Bravenboer, N.¹ Papapoulos, S.E.² Holzmann, P.³ Hamdy, N.A.T.⁴ Netelenbos, J.C.⁵ Lips, P.⁶

25
- 0030752221
- Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
- (1997) N Engl J Med , vol.337 , pp. 382-387
- Adachi, J.D.¹ Bensen, W.G.² Brown, J.³ Hanley, D.⁴ Hodsman, A.⁵ Josse, R.⁶ Kendler, D.L.⁷ Lentle, B.⁸ Olszynski, W.⁹ Ste-Marie, L.G.¹⁰ Tenenhouse, A.¹¹ Chines, A.A.¹²

26
- 18244431006
- Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
- Glucocorticoid-Induced Osteoporosis Intervention Study Group
- (1998) N Engl J Med , vol.339 , pp. 292-299
- Saag, K.G.¹ Emkey, R.² Schnitzer, T.J.³ Brown, J.P.⁴ Hawkins, F.⁵ Goemaere, S.⁶ Thamsborg, G.⁷ Liberman, U.A.⁸ Delmas, P.D.⁹ Malice, M.P.¹⁰ Czachur, M.¹¹ Daifotis, A.G.¹²

27
- 0034124416
- Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients
- (2000) Osteoporos Int , vol.11 , pp. 331-337
- Eastell, R.¹ Devogelaer, J.P.² Peel, N.F.³ Chines, A.A.⁴ Bax, D.E.⁵ Sacco-Gibson, N.⁶ Nagant de Deuxchaisnes, C.⁷ Russell, R.G.G.⁸

28
- 0034036235
- Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial
- (2000) J Bone Miner Res , vol.15 , pp. 1006-1013
- Reid, D.M.¹ Hughes, R.A.² Laan, R.F.J.M.³ Sacco-Gibson, N.A.⁴ Wenderoth, D.H.⁵ Adami, S.⁶ Eusebio, R.A.⁷ Devogelaer, J.P.⁸

29
- 0034739277
- Alendronate for the treatment of osteoporosis in men
- (2000) N Engl J Med , vol.343 , pp. 604-610
- Orwoll, E.¹ Ettinger, M.² Weiss, S.³ Miller, P.⁴ Kendler, D.⁵ Graham, J.⁶ Adami, S.⁷ Weber, K.⁸ Lorenc, R.⁹ Pietschmann, P.¹⁰ Vandormael, K.¹¹ Lombardi, A.¹²

30
- 0001373134
- Can alendronate be taken before lunch or dinner? A randomized trial in osteoporotic women
- Osteoporos Int , vol.11 , pp. S208
- Delmas, P.P.¹ Confavreux, E.² Genolet, G.³ Gamero, P.⁴ Gibelin, B.⁵ Folens, C.⁶ Yates, J.⁷

31
- 0027971721
- Structural requirements for bisphosphonate actions in vitro
- (1994) J Bone Miner Res , vol.9 , pp. 1875-1882
- Van Beek, E.¹ Hoekstra, M.² Van de Ruit, M.³ Lowik, C.⁴ Papapoulos, S.⁵

32
- 0025366467
- Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
- (1990) N Engl J Med , vol.322 , pp. 1265-1271
- Storm, T.¹ Thamsborg, G.² Steiniche, T.³ Genant, H.K.⁴ Sorensen, O.H.⁵

33
- 0025334778
- Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
- (1990) N Engl J Med , vol.323 , pp. 73-79
- Watts, H.B.¹ Harris, S.T.² Genant, H.K.³ Wasnich, R.D.⁴ Miller, P.D.⁵ Jackson, R.D.⁶ Licata, A.A.⁷ Ross, P.⁸ Woodson, G.C.⁹ Yanover, M.J.¹⁰ Mysiw, W.J.¹¹ Kohse, L.¹² Rao, M.B.¹³ Steiger, P.¹⁴ Richmond, B.¹⁵ Chesnut, C.H.¹⁶

34
- 0035070552
- Intermittent cyclical administration of filudronate in the treatment of osteoporosis
- (2001) Osteoporos Int , vol.12 , pp. 169-172
- Reginster, J.Y.¹ Christiansen, C.² Roux, C.³ Fechtenbaum, J.⁴ Rouillon, A.⁵ Tou, K.P.⁶

35
- 0006101869
- Oral clodronate significantly reduces fracture risk in women with postmenopausal or secondary osteoporosis
- (2000) J Bone Miner Res , vol.15 , pp. S227
- McCloskey, E.V.¹ Selby, P.² Davie, M.³

36
- 0027368467
- User's guide to medical literature. A. Are the results valid?
- (1993) JAMA , vol.270 , pp. 2598-2601
- Guyatt, G.H.¹ Sackett, D.L.² Cook, D.J.³

37
- 0002774122
- Bisphosphonates: Pharmacology and use in the treatment of osteoporosis
- Marcus R, Feldman D, Kelsey J (eds.). Academic Press, San Diego, CA, USA
- (1996) Osteoporosis , pp. 1209-1234
- Papapoulos, S.E.¹

38
- 0030678552
- Bone mineral density reflects bone mass but also the degree of mineralisation of bone: Therapeutic implications
- (1997) Bone , vol.21 , pp. 373-377
- Meunier, P.J.¹ Boivin, G.I.²

39
- 0033755981
- Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
- (2000) Bone , vol.27 , pp. 687-694
- Boivin, G.I.¹ Chavassieux, P.M.² Santora, A.C.³ Yates, J.⁴ Meunier, P.J.⁵

40
- 0030007961
- Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial
- (1996) Arthritis Rheum , vol.39 , pp. 396-402
- Eggelmeijer, F.¹ Papapoulos, S.E.² Van Paassen, H.C.³ Dijkmans, B.A.⁴ Valkema, R.⁵ Westedt, M.L.⁶ Landman, J.O.⁷ Pauwels, E.K.⁸ Breedveld, F.C.⁹

41
- 0029968633
- Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?
- (1996) Eur J Cancer , vol.32 A , pp. 450-454
- Van Holten-Verzantvoort, A.T.¹ Hermans, J.² Beex, L.V.³ Blijham, G.⁴ Cleton, F.J.⁵ Van Eck-Smit, B.C.⁶ Sleeboom, H.P.⁷ Papapoulos, S.E.⁸

42
- 0023520871
- Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD)
- (1987) BMJ , vol.295 , pp. 1301-1305
- Harinck, H.I.J.¹ Papapoulos, S.E.² Blanksma, H.J.³ Moolenaar, A.J.⁴ Vermeij, P.⁵ Bijvoet, O.L.M.⁶

43
- 0028606037
- Pamidronate: An unrecognized problem in gastrointestinal tolerability
- (1994) Osteoporos Int , vol.4 , pp. 320-322
- Lufkin, E.G.¹ Argueta, R.² Whitaker, M.D.³ Cameron, A.L.⁴ Wong, V.H.⁵ Egan, K.S.⁶ O'Fallon, W.M.⁷ Riggs, B.L.⁸

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.